These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 32108749

  • 1. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
    Xu KY, Tong S, Wu CY, Ding XC, Chen JL, Ming Y, Wang SH.
    Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T, Yoshimatsu G, Sakata N, Kawakami R, Tanaka T, Yamada T, Yoshida Y, Hasegawa S, Kodama S.
    Sci Rep; 2020 Oct 21; 10(1):17920. PubMed ID: 33087823
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
    Qu J, Yuan Z, Wang G, Wang X, Li K.
    Int Immunopharmacol; 2019 May 21; 70():147-155. PubMed ID: 30802677
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L, Wang S, Guzova J, Jiao A, Lin LL, Latz E, Hepworth D, Hall JP.
    J Immunol; 2016 Sep 15; 197(6):2421-33. PubMed ID: 27521339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T, Kritikou E, Venema W, van Duijn J, van Santbrink PJ, Slütter B, Foks AC, Bot I, Kuiper J.
    Arterioscler Thromb Vasc Biol; 2017 Aug 15; 37(8):1457-1461. PubMed ID: 28596375
    [Abstract] [Full Text] [Related]

  • 9. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W, Ba G, Tang R, Li M, Lin H.
    Int Immunopharmacol; 2020 Jun 15; 83():106394. PubMed ID: 32193102
    [Abstract] [Full Text] [Related]

  • 10. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A, Chen X, Shen J, Demetriades AM, Yao Y, Yao Y, Zhu Y, Shen X, Xie B.
    Cell Death Dis; 2020 Oct 22; 11(10):901. PubMed ID: 33093455
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O'Neill LA.
    Nat Med; 2015 Mar 22; 21(3):248-55. PubMed ID: 25686105
    [Abstract] [Full Text] [Related]

  • 14. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P, Wu D, Appel R, Zhang L, Zhang C, Luo W, Robertson AAB, Cooper MA, Coselli JS, Milewicz DM, Shen YH, LeMaire SA.
    J Am Heart Assoc; 2020 Apr 07; 9(7):e014044. PubMed ID: 32223388
    [Abstract] [Full Text] [Related]

  • 15. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM, Sugrue J, Rubio-Araiz A, Guillot-Sestier MV, Lynch MA.
    Sci Rep; 2019 Mar 11; 9(1):4034. PubMed ID: 30858427
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M, Yang Z, Zhang C, Shi Y, Han W, Song S, Mu L, Du C, Shi Y.
    Metabolism; 2021 May 11; 118():154748. PubMed ID: 33675822
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, Diep H, Kett MM, Samuel CS, Kemp-Harper BK, Robertson AAB, Cooper MA, Peter K, Latz E, Mansell AS, Sobey CG, Drummond GR, Vinh A.
    Cardiovasc Res; 2019 Mar 15; 115(4):776-787. PubMed ID: 30357309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.